Phase
II
study evaluating the association of gemcitabine, trastuzumab and erlotinib as first‐line treatment in patients with metastatic pancreatic adenocarcinoma (
GATE
1)
2014 ◽
Vol 50
(18)
◽
pp. 3116-3124
◽